179
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
COMPARATIVE ANALYSIS OF GLUCOCORTICOID PRICES IN THE
TREATMENT OF RHEUMATOID ARTHRITIS
Seytniyazova B.M.
Suyunov N.D.
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: suyunovn.d.5555@gmail.com
https://doi.org/10.5281/zenodo.17332518
Relevance:
rheumatoid arthritis is a chronic autoimmune disease of connective tissue,
characterized by progressive joint damage and deformity, as well as the development of disability.
Contemporary pharmacotherapy includes disease-modifying ant rheumatic drugs, biological agents,
and symptomatic treatment. Glucocorticoids are administered in combination with other therapeutic
agents and play an important role in controlling the inflammatory process and managing disease
exacerbations. International and national clinical guidelines confirm their efficacy and widespread
application, which highlights the relevance of analyzing the availability of these medications.
Purpose of the study:
is to conduct a comparative analysis of the prices of prednisolone and
methylprednisolone recommended in the national clinical protocol for the treatment of rheumatoid
arthritis.
Materials and methods:
the study utilized data from the "Farm Portal" ("Reference Price List")
as of September 14, 2025. A comparative analysis was performed on the retail prices of prednisolone
and methylprednisolone pharmaceutical products, categorized by international non-proprietary
names and brand names, with consideration of dosage forms and manufacturers.
Results:
the analysis revealed that the range of prednisolone and methylprednisolone
medications is represented by multiple brand names produced by different manufacturers.
№ Internation
al non-
propriety
name
Brand names
Manufacturer
Retail
price,
UZS
Country of
origin
1
Prednisolon
e
Prednisolone -RG 30
mg/ml, 1 ml, № 5
(1x5)
Remedy Group
JV Ltd.
23,184
Uzbekistan
2
Prednisolone 30
mg/ml 1 ml, № 10
Radiks Ltd.
34,003.2
Uzbekistan
3
Prednisolone -RG 30
mg/ml, 1 ml , №10
(2x5)
Remedy Group
JV Ltd.
30,912
Uzbekistan
4
Prednisolone 30
mg/ml 1 ml, № 10
(2x5)
Ellara Ltd.
29,951.1
4
Russia
5
Prednisolone 30
mg/ml 1 ml, № 5
(1x5)
Uzgermed Pharm
JV Ltd.
33,120
Uzbekistan
6
Prednisolone SD 5
mg, № 50 (5x10)
Sharq Darmon
Ltd.
29,566.5
Uzbekistan
180
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
7
Prednisolone 5 mg, №
40 (2x20)
JSC Vinh phuc
pharmaceutical
41,659.6
1
Vietnam
8
Prednisolone-
Darnytsia 5 mg, № 40
(4x10)
PrJSC Darnytsia
34,211.5
7
Ukraine
9
Prednisolone 5 mg, №
100 (10x10)
Co.ltd. Shandong
Xier Kangtai
Pharmaceutical
35,671.4
8
China
10
Prednisolone 30
mg/ml 1 ml, № 3
(3x1)
Agio
Pharmaceuticals
Ltd.
18,006.1
India
11
Prednisolone 5 mg, №
100 (10x10)
Aburaihan
Pharmaceutical
Co.
54,282.0
3
Iran
12
Methylpred
nisolone
Solu-Medrol 500 mg
Pfizer
Manufacturing
Belgium NV
272,189.
92
Belgium
13
Solu-Medrol 1000 mg
Pfizer
Manufacturing
Belgium NV
571,385.
76
Belgium
14
Avimedrol 4 mg, №
30 (3x10)
Avantika Medex
Pvt. Ltd.
112,690.
57
India
15
Avimedrol 16 mg, №
30 (3x10)
Avantika Medex
Pvt. Ltd.
270,457.
37
India
16
Slideron 4 mg, № 20
(2x10)
AD
Balkanpharma-
Razgrad
89,931.0
4
Bulgaria
17
Slideron 16 mg, № 20
(2x10)
AD
Balkanpharma-
Razgrad
213,975.
24
Bulgaria
18
Slideron 500 mg
LTD United
Biotech (P)
134,363.
7
India
The range of prednisolone medications is represented by different formulations: ampoules (30
mg/ml) priced from 18,006.1 to 34,003.2 UZS, and tablets (5 mg) priced from 29,566.5 to 54,282.03
UZS. The range of methylprednisolone medications includes intravenous formulations (500-1000
mg) priced from 134,363.7 to 571,385.76 UZS, and tablets (4-16 mg) priced from 89,931.04 to
270,457.37 UZS. These findings indicate that methylprednisolone constitutes a significantly more
expensive therapeutic option compared to prednisolone, with the greatest cost difference observed
for injections.
Conclusions:
the comparative analysis demonstrated that methylprednisolone pharmaceutical
products are, on average, 3-10 times more expensive than prednisolone, which may substantially
reduce their accessibility for patients. Furthermore, the price variation within each drug group reaches
181
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
up to twofold, indicating considerable market heterogeneity. These findings underscore the necessity
of incorporating price considerations into strategies for ensuring equitable access to essential
medicines. They also emphasize the importance of rational drug selection within clinical protocols
and the potential need for policy measures aimed at improving affordability and optimizing resource
allocation in healthcare systems.
